Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis

Blood

Volumn 116, Issue 6, 2010, Pages 1002-1010

  Silasi Mansat, Robert ^a   Zhu, Hua ^a,b   Popescu, Narcis I ^a,b   Peer, Glenn ^b   Sfyroera, Georgia ^c   Magotti, Paola ^c   Ivanciu, Lacramioara ^a   Lupu, Cristina ^a   Mollnes, Tom E ^d,e   Taylor, Fletcher B ^a,b   Kinasewitz, Gary ^b   Lambris, John D ^c   Lupu, Florea ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955901581     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-269746     Document Type: Article

References (40)

1. Ward PA, Gao H. Sepsis, Complement, and the Dysregulated Inflammatory Response. J Cell Mol Med. 2009.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-1310. (Pubitemid 32641789)
3. Taylor FB, Jr. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med. 2001;29(7 Suppl):S78-89.
4. Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. J Cell Mol Med. 12(6A):2245-2254, 2008.
5. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171 (3):715-727. (Pubitemid 47440971)
6. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004;4(2):133-142.
7. de Boer JP, Creasey AA, Chang A, et al. Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immun. 1993;61(10):4293-4301. (Pubitemid 23298587)
8. Taylor FB, Jr., Hack E, Lupu F. Observations on complement activity in the two-stage inflammatory/hemostatic response in the baboon and human models of E coli sepsis and endotoxemia. Adv Exp Med Biol. 2006;586:203-216.
9. Bengtsson A, Redl H, Paul E, Schlag G, Mollnes TE, Davies J. Complement and leukocyte activation in septic baboons. Circ Shock. 1993;39(2):83-88. (Pubitemid 23057745)
10. Stahl GL, Xu Y, Hao L, et al. Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol. 2003;162(2):449-455. (Pubitemid 36267852)
11. Katragadda M, Magotti P, Sfyroera G, Lambris JD. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006;49(15):4616-4622. (Pubitemid 44162688)
12. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol. 1996;157(2):884-891. (Pubitemid 26231396)
13. Taylor FB, Jr., Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 2000;95(5):1680-1686. (Pubitemid 30120829)
14. Tang H, Ivanciu L, Popescu N, et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol. 2007;171(3):1066-1077. (Pubitemid 47441003)
15. Gong J, Larsson R, Ekdahl KN, Mollnes TE, Nilsson U, Nilsson B. Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol. 1996;16(4):222-229. (Pubitemid 26249187)
16. Soulika AM, Khan MM, Hattori T, et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol. 2000;96(3):212-221.
17. Sfyroera G, Katragadda M, Morikis D, Isaacs SN, Lambris JD. Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol. 2005;174(4):2143-2151. (Pubitemid 40223958)
18. Mollnes TE, Redl H, Hogasen K, et al. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol. 1993;91(2):295-300. (Pubitemid 23045677)
19. Lupu C, Westmuckett AD, Peer G, et al. Tissue factor-dependent coagulation is preferentially upregulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol. 2005;167(4):1161-1172. (Pubitemid 41416266)
20. Zhu H, Tang Y, Ivanciu L, et al. Temporal dynamics of gene expression in the lung in a baboon model of E coli sepsis. BMC Genomics. 2007;8:58. (Pubitemid 46403176)
21. Janssen BJ, Halff EF, Lambris JD, Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem. 2007;282(40):29241-29247. (Pubitemid 350043342)
22. Sahu A, Morikis D, Lambris JD. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol. 2003;39(10):557-566. (Pubitemid 35335834)
23. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184-192. (Pubitemid 46476881)
24. Sims PJ, Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today. 1991;12(9):338-342.
25. Ohmi Y, Tajima O, Ohkawa Y, Mori A, Sugiura Y, Furukawa K. Gangliosides play pivotal roles in the regulation of complement systems and in the maintenance of integrity in nerve tissues. Proc Natl Acad Sci U S A. 2009.
26. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201(6):871-879. (Pubitemid 40524457)
27. Polley MJ, Nachman RL. Human platelet activation by C3a and C3a des-arg. J Exp Med. 1983;158(2):603-615.
28. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114(5-6):321-327.
29. Wojta J, Kaun C, Zorn G, et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood. 2002;100(2):517-523. (Pubitemid 34761114)
30. Taylor FB, Jr. Studies on the inflammatory-coagulant axis in the baboon response to E coli: regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Prog Clin Biol Res. 1994;388:175-194.
31. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161-3172.
32. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4):345-357.
33. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12(6):682-687. (Pubitemid 43865238)
34. Binette TM, Taylor FB, Jr., Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood. 2007;110(9):3168-3175. (Pubitemid 350106308)
35. Kinasewitz GT, Zein JG, Lee GL, Nazir SA, Taylor FB, Jr. Prognostic value of a simple evolving disseminated intravascular coagulation score in patients with severe sepsis. Crit Care Med. 2005;33(10):2214-2221.
36. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, Nilsson B. Complement Component C3 Binds to Activated Normal Platelets without Preceding Proteolytic Activation and Promotes Binding to Complement Receptor 1. J Immunol. 2010.
37. Thorgersen EB, Hellerud BC, Nielsen EW, et al. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 2009.
38. Lappegard KT, Christiansen D, Pharo A, et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci U S A. 2009;106(37):15861-15866.
39. Mollnes TE, Christiansen D, Brekke OL, Espevik T. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv Exp Med Biol. 2008;632:253-263.
40. Brekke OL, Christiansen D, Fure H, et al. Combined inhibition of complement and CD14 abolish E coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. Mol Immunol. 2008;45(14):3804-3813.